BioWorld

June 9, 2005

On Heels Of VX-950 Data, Vertex Gathers Up $153M

Vertex Pharmaceuticals Inc. sold 11.75 million shares to raise gross proceeds of $152.8 million, the second highest amount of any biotech follow-on or initial public offering this year. (BioWorld Today) Read More

Panel Confirms Positive Data For Erbitux In Phase III Trial

Osiris Brings In $50M To Fund Stem Cell-Based Therapeutics

Gates Foundation Awards $22M Grant To Hookworm Research

Correction

Other News To Note

NIH changes set industry up for workforce, ideas drought

BioWorld

On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...

Today's news in brief

BioWorld

BioWorld briefs for March 6, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 6, 2025

Roche looks to grow with sequencing by expansion tech

BioWorld MedTech

Roche Holding AG revealed plans to launch its sequencing by expansion technology next year, raising the possibility that rival Illumina Inc. could face a real run...

Illustration of Magnet Biomedicine's Trueglue platform

Magnet, Eli Lilly sign $1.25B molecular glue deal for oncology

BioWorld

About 17 months after emerging from stealth with its Trueglue discovery platform, Magnet Biomedicine Inc. has joined with Eli Lilly and Co. to discover, develop...